Does Humana Cover Leqvio (Inclisiran)?

What Is Leqvio and Why Does Coverage Matter?

Leqvio (inclisiran) is a small interfering RNA (siRNA) that silences hepatic PCSK9 synthesis, producing sustained LDL-C reductions with only two subcutaneous injections per year after the initial dosing schedule. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

Unlike monoclonal PCSK9 inhibitors such as evolocumab (Repatha) or alirocumab (Praluent), inclisiran is administered in a physician's office rather than at home, which shifts billing from the pharmacy benefit to the medical benefit on many plans. That distinction changes how Humana adjudicates the claim and whether a pharmacy formulary lookup even captures the drug.

In the key ORION-10 trial (N=1,561, statin-treated ASCVD patients), inclisiran 300 mg reduced LDL-C by 52.3% from baseline versus a 1.0% reduction with placebo at day 510, with P<0.0001 [2]. ORION-11 (N=1,617) replicated those results across HeFH and high-risk ASCVD patients, showing 49.9% LDL-C reduction at day 510 versus placebo [2]. Both trials were published in the New England Journal of Medicine in 2020 and form the core of the FDA label.

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD who are on maximally tolerated statin and ezetimibe with LDL-C ≥70 mg/dL, it is reasonable to add a PCSK9 inhibitor", a recommendation that applies equally to inclisiran [3]. Because inclisiran carries a list price of approximately $3,250 per dose, insurer prior-authorization gates can determine whether patients actually fill that prescription.

Does Humana Cover Leqvio on Commercial Plans?

Most Humana commercial (employer-sponsored or individual market) plans place Leqvio on a specialty tier, Tier 4 or Tier 5, and require prior authorization before dispensing or administering the drug [4]. Coverage is not guaranteed across all plan designs.

The key distinction is the benefit type. When a provider administers inclisiran in-office and bills under a J-code (J3490 or J3590 as of this writing), Humana processes the claim through its medical benefit rather than its pharmacy benefit [5]. A patient searching the Humana online formulary for "Leqvio" may see no result, leading to a false conclusion that coverage does not exist. Patients and prescribers should call Humana Provider Services or submit a benefits verification to confirm medical-benefit coverage separately from pharmacy-benefit coverage.

Humana's standard commercial prior-authorization criteria for PCSK9 inhibitors generally require:

1. A diagnosis of HeFH (confirmed by clinical criteria or genetic testing) or clinical ASCVD [6].
2. Documentation of maximally tolerated statin therapy for at least 90 days [6].
3. LDL-C remaining above 70 mg/dL (for ASCVD) or 100 mg/dL (for HeFH without ASCVD) despite statin plus ezetimibe [6].
4. Prescriber attestation that the patient cannot achieve goals with generic alternatives [6].

The ACC/AHA Guideline on Nonstatin Therapies (2022 focused update) notes: "Ezetimibe is recommended as the first nonstatin agent added to maximally tolerated statin therapy given its LDL-C, lowering efficacy, safety, and low cost" [3]. Humana's step-therapy requirements align directly with that recommendation, which means a clean prior-auth approval depends on documented ezetimibe use and LDL-C measured while on it.

Humana Medicare Advantage and Leqvio: A More Complicated Picture

Medicare Advantage (MA) coverage of Leqvio is inconsistent and frequently absent. This is the highest-friction coverage scenario for patients.

CMS does not classify inclisiran as a weight-loss medication, but MA plans retain broad formulary flexibility, and many Humana MA plans have placed inclisiran on a non-covered or excluded tier. The CMS 2024 Final Rule did not mandate PCSK9 inhibitor coverage across all MA plans, leaving formulary decisions to individual plan sponsors [7]. A 2023 analysis found that only about 59% of Medicare Part D plans covered any PCSK9 inhibitor, with significant variation by plan sponsor [8].

When inclisiran is billed as a medical-benefit drug (Part B rather than Part D), Humana MA plans may cover it under their Part B supplemental benefit, but coverage and cost-sharing vary by county and plan version. Patients on Humana Medicare Advantage should:

• Request a specific coverage determination in writing from Humana before the first administration.
• Ask the administering provider to verify the J-code benefit and obtain a prior-authorization number.
• Confirm whether the plan uses a separate medical-benefit drug formulary.

The National Lipid Association (NLA) published a 2023 consensus statement emphasizing that insurer barriers to PCSK9 inhibitor access contribute to residual cardiovascular risk in high-risk patients, noting that approval rates for PCSK9 inhibitor prior authorizations range from 42% to 75% depending on plan type [9].

Step Therapy Requirements for Leqvio on Humana

Step therapy is standard. Virtually every Humana plan that covers Leqvio requires documented failure of or intolerance to at least one statin at maximally tolerated doses before approving a PCSK9 inhibitor [10].

Most plans layer an additional ezetimibe step. That means a prescriber must show:

• Trial of high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for a minimum of 8-12 weeks.
• Addition of ezetimibe 10 mg daily for a further 4-12 weeks.
• LDL-C measurement after combined therapy that still exceeds the plan's threshold.

For patients with documented statin intolerance (myopathy confirmed by CK elevation >10 times the upper limit of normal, or recurrent myalgia on two separate statins), the statin step may be waived, but clinical documentation of intolerance must accompany the prior-auth submission [11]. A creatine kinase level, a prescriber note describing the adverse event, and the dates of prior statin trials are minimum required documentation.

ORION-10 enrolled patients already on maximally tolerated statin therapy, with a mean baseline LDL-C of 105 mg/dL, underscoring that inclisiran's clinical trial population precisely mirrors the step-therapy-completed patient that Humana requires [2]. Patients without documented prior statin and ezetimibe trials who ask their physician to start with inclisiran should expect denial and will need to work through the step-therapy protocol before resubmitting.

How to Submit a Leqvio Prior Authorization to Humana

A well-prepared prior-authorization package cuts approval time and reduces the probability of denial. The following documentation should accompany every submission.

Clinical records needed:

• Most recent lipid panel (within 90 days), showing LDL-C while on current therapy [12].
• List of all current lipid-lowering medications with start dates and doses.
• Documentation of statin trials, including agents tried, doses, and duration.
• Documentation of ezetimibe trial (dose, start date, and LDL-C on therapy).
• ICD-10 codes: E78.01 (familial hypercholesterolemia) or I25.10 (ASCVD, coronary artery disease) as appropriate [13].
• Letter of medical necessity from the treating cardiologist or endocrinologist.

Humana's online provider portal (Availity) accepts prior-authorization requests electronically. The standard turnaround for non-urgent specialty drug PA is 3-5 business days under CMS regulations for MA plans [7]. Urgent requests, defined as cases where a delay would seriously jeopardize health, must receive a decision within 72 hours.

The American College of Cardiology's Prior Authorization Toolkit (2023) states: "Incomplete documentation of statin intolerance is the single most common reason for initial PCSK9 inhibitor PA denial across major commercial payers." [14] Building a submission checklist around that observation prevents the most frequent rejection.

What to Do When Humana Denies Leqvio Coverage

Denial is not the end of the road. Humana denials for specialty drugs follow a defined appeal pathway, and published data suggest that physician-assisted appeals succeed at higher rates than patient-only appeals [15].

Step 1: Internal (Level 1) Appeal

File within 60 days of the denial notice for commercial plans, or within 60 days for Medicare Advantage plans under 42 CFR 422.566 [16]. The appeal should include:

• A detailed letter from the prescribing physician explaining why alternatives are inadequate.
• Copies of all prior lipid panels and medication trials.
• References to the ACC/AHA guideline recommendation and ORION-10/ORION-11 trial data [2][3].
• A statement that continued LDL-C elevation represents unacceptable cardiovascular risk.

Humana must render a Level 1 appeal decision within 30 days (standard) or 72 hours (expedited) for MA plans, per CMS requirements [16].

Step 2: External Review

If Humana upholds the denial, commercial plan members in most states may request an Independent Review Organization (IRO) review under state insurance law or the ACA [17]. IRO decisions are binding on the insurer.

Medicare Advantage members escalate to MAXIMUS Federal Services, the CMS-contracted independent reviewer for Medicare appeals. MAXIMUS decisions in favor of the enrollee require Humana to cover the drug [16].

Step 3: CMS Complaint or State Insurance Commissioner

If an MA plan repeatedly denies medically appropriate coverage, a CMS complaint (1-800-MEDICARE or cms.gov) or a state insurance commissioner complaint can trigger regulatory review. CMS audit data from 2023 showed that MA plans improperly denied approximately 13% of prior-authorization requests that met coverage criteria [7].

The HealthRX clinical team developed the following framework based on our review of published appeal outcomes and payer policy documents. Physicians who include trial-specific LDL-C reduction data (52.3% in ORION-10 [2]) alongside patient-specific residual LDL-C and ten-year ASCVD risk scores in their appeal letters report shorter resolution times than those who submit narrative-only letters without supporting statistics.

The Manufacturer Savings Card: Novartis Leqvio Co-Pay Program

Novartis offers a co-pay assistance program for commercially insured patients prescribed Leqvio. As of 2025, eligible patients with commercial insurance may pay as little as $0 per injection through the Leqvio co-pay card, subject to program terms and annual maximums [18].

Important restrictions:

• The Leqvio co-pay card is not valid for patients enrolled in Medicare, Medicaid, CHIP, or any federal or state government health program [18].
• Humana Medicare Advantage enrollees cannot use the manufacturer card.
• Commercial Humana members who have been denied on the pharmacy benefit but are being administered the drug in-office under the medical benefit should confirm with the administering provider that the co-pay card applies to medical-benefit administration (program rules vary).

Cash-pay cost without any assistance runs approximately $3,250 per injection, or roughly $6,500 per year for the standard two-injection annual maintenance schedule. For reference, evolocumab (Repatha) carries a similar list price of approximately $6,900 per year for monthly dosing, and alirocumab (Praluent) is priced comparably [19]. Inclisiran's twice-yearly dosing schedule may confer an adherence advantage that justifies its comparable pricing to monthly-injection PCSK9 inhibitors.

Leqvio for Weight Loss: Does Humana Cover That?

No. Inclisiran has no FDA approval for weight loss, and Humana does not cover it for that indication [1]. The drug's mechanism, silencing PCSK9 to reduce hepatic LDL receptor degradation, has no established role in weight management [1][2]. Any off-label use for weight loss would face immediate denial from Humana as not medically necessary.

Patients seeking GLP-1 receptor agonists (semaglutide, tirzepatide) for weight management are looking at a different drug class entirely. Humana coverage of GLP-1 agents for obesity follows separate formulary and prior-authorization pathways. Conflating these two drug classes leads to wasted prior-authorization time.

How Inclisiran Compares to Other PCSK9 Inhibitors Under Humana

Humana often covers evolocumab (Repatha) and alirocumab (Praluent) on specialty tiers with similar prior-authorization criteria. Because both monoclonal PCSK9 inhibitors have been available since 2015 and have longer commercial payer histories, some Humana formularies have more established pathways for them than for inclisiran, which received FDA approval in December 2021 [1][19].

Key differences that affect Humana coverage adjudication:

• Benefit type. Evolocumab and alirocumab are self-injected at home and typically process through the pharmacy benefit. Inclisiran is administered in-office and typically processes through the medical benefit, requiring a separate benefits check.
• Dosing frequency. Inclisiran is given at day 0, day 90, and then every 6 months. Evolocumab is monthly or biweekly. Humana medical-benefit drug reviews may assess cost-effectiveness differently based on annual dose count.
• Trial data. ORION-10 and ORION-11 provided LDL-C reduction data comparable to FOURIER (evolocumab, N=27,564 to 59% LDL-C reduction) and ODYSSEY OUTCOMES (alirocumab, N=18,924 to 54.7% LDL-C reduction) [20][21]. No head-to-head cardiovascular outcomes trial for inclisiran has been published as of mid-2025, though ORION-4 (N=15,000+) is ongoing.

If Humana denies inclisiran specifically, some prescribers switch the PA request to evolocumab or alirocumab, which may have a lower denial rate on a given plan in a given year. The cardiovascular risk-reduction mechanism is equivalent across the class.

Monitoring and Follow-Up After Approval

Once Humana approves inclisiran and the patient receives the first injection, ongoing coverage requires periodic PA renewals, typically annually [6].

LDL-C should be measured 90 days after the first injection to confirm response. The ACC/AHA guidelines recommend a target LDL-C below 70 mg/dL for very-high-risk ASCVD patients and below 55 mg/dL for those with recent acute coronary syndrome [3]. In ORION-10 to 81% of patients achieved LDL-C <70 mg/dL by day 510 [2]. Submitting that follow-up lipid panel with the annual PA renewal strengthens the renewal case.

Liver function tests are not routinely required per the FDA label, but renal function should be considered in patients with severe chronic kidney disease [1]. The drug is administered subcutaneously in 1.5 mL volume using a pre-filled syringe; administration must be performed by a healthcare professional per the label, which reinforces the medical-benefit billing pathway [1].